tezosentan has been researched along with Dyspnea in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Teerlink, JR | 1 |
Bourge, RC; Cleland, JG; Cotter, G; Frey, A; Jondeau, G; Kobrin, I; Krum, H; Lewsey, J; McMurray, JJ; Metra, M; O'Connor, CM; Parker, JD; Rainisio, M; Teerlink, JR; Torre-Amione, G; van Veldhuisen, DJ | 1 |
1 review(s) available for tezosentan and Dyspnea
Article | Year |
---|---|
Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure.
Topics: Acute Disease; Drug Approval; Dyspnea; Forecasting; Heart Failure; Hospitalization; Humans; Hydrazones; Natriuretic Agents; Natriuretic Peptide, Brain; Pyridazines; Pyridines; Randomized Controlled Trials as Topic; Severity of Illness Index; Simendan; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2003 |
1 trial(s) available for tezosentan and Dyspnea
Article | Year |
---|---|
Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
Topics: Acute Disease; Aged; Cardiac Output; Double-Blind Method; Dyspnea; Endothelin Receptor Antagonists; Female; Heart Failure; Humans; Infusions, Intravenous; Male; Pulmonary Wedge Pressure; Pyridines; Tetrazoles; Treatment Outcome; Vascular Resistance; Vasodilator Agents | 2007 |